ArticleJournal of virology1999
Herpes simplex virus type 2 glycoprotein G-negative clinical isolates are generated by single frameshift mutations.
Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- British Association of Sexual Health and HIV UK national guideline for the management of anogenital herpes, 2024.International journal of STD & AIDS · 2025Guideline
- Glycoprotein G enables HSV-2 neuroinvasion and provides protection as a glycosylated vaccine antigen.PLoS pathogens · 2026Article
- HSV-2 gE2/gI2 are immune evasion molecules that bind IgG Fc to inhibit antibody-dependent cellular cytotoxicity.Frontiers in immunology · 2026Article
- Identification of the Cleavage Domain within Glycoprotein G of Herpes Simplex Virus Type 2.Viruses · 2020Article
- Article
- The herpes simplex virus 2 virion-associated ribonuclease vhs interferes with stress granule formation.Journal of virology · 2014Article
- Diagnosis of genital herpes simplex virus infection in the clinical laboratory.Virology journal · 2014Review
- Stability of glycoprotein gene sequences of herpes simplex virus type 2 from primary to recurrent human infection, and diversity of the sequences among patients attending an STD clinic.BMC infectious diseases · 2014Article
- Evolution and diversity in human herpes simplex virus genomes.Journal of virology · 2014Article
- Molecular characterization of herpes simplex virus 2 strains by analysis of microsatellite polymorphism.Journal of clinical microbiology · 2013Article
- Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.Journal of virology · 2012Article
- A wide extent of inter-strain diversity in virulent and vaccine strains of alphaherpesviruses.PLoS pathogens · 2011Article
- Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.Molecular pharmaceutics · 2010Article
- Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland.Clinical and vaccine immunology : CVI · 2008Article
- Herpes simplex virus type 2 glycoprotein G is targeted by the sulfated oligo- and polysaccharide inhibitors of virus attachment to cells.Journal of virology · 2007Article
- Divergence and recombination of clinical herpes simplex virus type 2 isolates.Journal of virology · 2007Article
- Performance of two commercial enzyme-linked immunosorbent assay kits using recombinant glycoprotein G2 antigen for detection of herpes simplex virus type 2 specific antibodies.Clinical and diagnostic laboratory immunology · 2005Article
- Production of herpes B virus recombinant glycoproteins and evaluation of their diagnostic potential.Journal of clinical microbiology · 2005Article
- Performance and use of a ribonucleotide reductase herpes simplex virus type-specific serological assay.Clinical and diagnostic laboratory immunology · 2004Article
- Secreted portion of glycoprotein g of herpes simplex virus type 2 is a novel antigen for type-discriminating serology.Journal of clinical microbiology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus (HSV) codes for several envelope glycoproteins, including glycoprotein G-2 (gG-2) of HSV type 2 (HSV-2), which are dispensable for replication in cell culture. However, clinical isolates which are deficient in such proteins occur rarely. We describe here five clinical HSV-2 isolates which were found to be unreactive to a panel of anti-gG-2 monoclonal antibodies and therefore considered phenotypically gG-2 negative. These isolates were further examined for expression of the secreted amino-terminal and cell-associated carboxy-terminal portions of gG-2 by immunoblotting and radioimmunoprecipitation. The gG-2 gene was completely inactivated in four isolates, with no expression of the two protein products. For one isolate a normally produced secreted portion and a truncated carboxy-terminal portion of gG-2 were detected in virus-infected cell medium. Sequencing of the complete gG-2 gene identified a single insertion or deletion of guanine or cytosine nucleotides in all five strains, resulting in a premature termination codon. The frameshift mutations were localized within runs of five or more guanine or cytosine nucleotides and were dispersed throughout the gene. For the isolate for which a partially inactivated gG-2 gene was detected, the frameshift mutation was localized upstream of but adjacent to the nucleotides coding for the transmembranous region. Thus, this study demonstrates the existence of clinical HSV-2 isolates which do not express an envelope glycoprotein and identifies the underlying molecular mechanism to be a single frameshift mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.